What's Going On With Pfizer Stock Thursday?
What's Going On With Pfizer Stock Thursday?
Pfizer, Inc. (NYSE:PFE) shares are slightly higher on Thursday after the European Commission approved Pfizer's DURVEQTIX.
辉瑞（NYSE:PFE）股价于周四略有上涨，此前欧盟批准了辉瑞的DURVEQTIX。
Pfizer announced Thursday that the European Commission approved a conditional marketing authorization for DURVEQTIX, a gene therapy for severe and moderately severe hemophilia B in adults whom meet certain criteria.
辉瑞周四宣布欧盟批准了DURVEQTIX的有条件上市授权，该基因疗法可治疗成年严重和中度严重的血友病B患者，条件是符合特定标准。
Hemophilia B is a rare genetic disorder that impairs blood clotting due to a deficiency in Factor IX, leading individuals with the condition to experience more frequent and prolonged bleeding.
血友病B是一种罕见的遗传性疾病，由于因子IX缺乏而导致血液凝固能力下降，使患者更容易出血且出血时间较长。
"DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with hemophilia B. These outcomes and their impact could become potentially transformative for hemophilia B care in the European Union," said chief international commercial officer and executive vice president at Pfizer Alexandre de Germay.
辉瑞国际商业主管兼执行副总裁Alexandre de Germay表示：“DURVEQTIX已经展示了在一次用药中提供长期止血保护的潜力，能够降低或消除血友病B合适患者的出血，这些结果及其影响有望对欧盟的血友病B治疗产生巨大的改变。”
DURVEQTIX is already approved in the United States and Canada.
DURVEQTIX已经在美国和加拿大获得批准。
For the 2024 fiscal year second quarter, analyst estimates an EPS of 46 cents and revenue of $13.02 billion.
根据分析师的预测，2024财年第二季度每股收益为46美分，营业收入为130.2亿美元。
Related Link: GOP Strategist Asks Republicans To Challenge Joe Biden On Drug Pricing: 'Go After It'
相关链接：共和党战略家呼吁共和党人在药价问题上挑战乔·拜登：“去做吧”。
PFE Price Action: At the time of writing, Pfizer shares are trading 1.55% higher $30.45 per data from Benzinga Pro.
PFE股价走势：截至撰写时，辉瑞股票交易价格为每股30.45美元，涨幅为1.55%，数据来自Benzinga Pro。
Image: Photo via Shutterstock
图像：通过shutterstock拍摄